FTSE MIB
34.209,56 +58,15 (+0,17%) Dow Jones
39.161,67 +105,28 (+0,27%) Nasdaq
16.284,83 -17,93 (-0,11%) Nikkei 225
38.073,98 -128,39 (-0,34%) Petrolio
79,45 +0,46 (+0,58%) Bitcoin EUR
57.003,73 -824,29 (-1,43%)
Cognition Therapeutics, Inc. (CGTX)
| Chiusura precedente | 2,0000 |
| Aperto | 1,9500 |
| Denaro | 1,8900 x 100 |
| Lettera | 2,0800 x 100 |
| Min-Max giorno | 1,9402 - 2,0200 |
| Intervallo di 52 settimane | 0,9000 - 3,4900 |
| Volume | |
| Media Volume | 199.803 |
| Capitalizzazione | 80,117M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8600 |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,67 |
GlobeNewswireCognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
Complete EEG results from SEQUEL study to be unveiled, demonstrating beneficial impact of CT1812 on brain synaptic function CT1812 START study in early Alzheimer’s disease allows approved monoclonal antibody as background therapy – featured as late-breaking, oral presentation PURCHASE, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced upcoming presentations from studies of CT1812, the Company's lead candidate for the tr
- GlobeNewswire
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth “Conversations” video podcast, which features an interactive discussion with retinal specialists about dry age-related macular degeneration (dry AMD) and the current treatment landscape. Dry AMD is caused by a degeneration of the macula and gradual loss of central vision. An estimated 1.5 million people in the United States are affected by late-st
- GlobeNewswire
Cognition Therapeutics Announces Participation in Upcoming September Conferences
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conferen
